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Objectives. To determine the prevalence of insulin resistance (IR) and its predictors in reproductive-aged Thai women with
polycystic ovary syndrome (PCOS). Methods. A cross-sectional study was conducted from May 2007 to January 2009. Participants
were 250Thai women with PCOS. Information regarding medical history and physical examination and results of 75 gram OGTT
were recorded. Results. The overall prevalence of IR was 20.0%, comprising the prevalence of impaired fasting glucose, impaired
glucose tolerance, and diabetic mellitus of 3.2%, 13.6%, and 5.6%, respectively. Multiple logistic regression analysis showed that
theindependentpredictorsforIRwereageof ≥30yearsold,waistcircumference(WC)of ≥80cm,presenceofacanthosisnigricans
(AN),anddyslipidemiawithoddsratios(95%conﬁdenceinterval)of2.14(1.01–4.52),3.53(1.28–9.75),2.63(1.17–5.88),and3.07
(1.16–8.11), respectively. Conclusion. The overall prevalence of IR in reproductive-aged Thai women with PCOS is 20.0%. Age ≥30
years old, WC ≥80cm, the presence of AN, and dyslipidemia are the signiﬁcant clinical predictors.
1.Introduction
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders, aﬀecting around 4–7% of re-
productive-aged women [1]. The etiology of PCOS remains
to be elucidated, although insulin resistance (IR) and hyper-
insulinemia seem to be the important mechanism for PCOS
and its metabolic derangements [2, 3], diabetes mellitus
(DM) in particular [4, 5]. It has been reported that PCOS
women are at high risk of IR as shown by various markers,
forexample,impairedglucosetoleranceof25–31%,andtype
2D Mo f7 . 5 – 1 0 %[ 6, 7].
Patients with IR, especially those with DM, have a high
risk for developing cardiovascular disease in the future
[8, 9]. Although PCOS women have a high risk of IR,
the Rotterdam ESHRE/ASRM-sponsored PCOS Consensus
Workshop Group does not recommend any test of IR to be
routinely used in clinical practice. However, it is suggested
that in large-scale clinical or epidemiological studies, simple
methods such as fasting plasma glucose (FPG) and oral glu-
cose tolerance test (OGTT) may provide eﬀective estimates
for IR [10].
In our previous report [11], we found that the PCOS
women at our clinic were relatively young and thin as
compared with those in other reports [6, 7, 12]. This
speciﬁc group of PCOS women might have lower risk of
IR. The objectives of the present study were to investigate
the prevalence and clinical predictors of IR in PCOS Thai
women.
2.MaterialsandMethods
The present cross-sectional study was conducted at the
Gynecologic Endocrinology Unit, Faculty of Medicine Siri-
raj Hospital, Mahidol University. The study protocol was
approved by the Siriraj Institutional Review Board.2 International Journal of Endocrinology
2.1. Participants. Participants were all PCOS Thai women
who registered to the Siriraj PCOS project from May 2007
to January 2009 [11]. The diagnosis of PCOS was made
according to the revised Rotterdam 2003 criteria [10].
Additional exclusion criteria were women who had previous
surgery of one or both ovaries, used hormonal treatment,
took the medication for dyslipidemia within 3 months,
or took steroid within 6 months before registering to the
project.
After a written informed consent was obtained, a struc-
tured medical record form was used to collect the following
data: clinical presentation, medical history, age, body weight,
height, waist circumference (WC), blood pressure, and skin
manifestations. The detailed method of clinical examination
was published in our previous report [11].
Glucose tolerance was evaluated using 75g OGTT.
Venous blood samples were drawn twice from antecubital
vein. The ﬁrst sample was drawn at 8–10 AM after overnight
fasting for at least 12 hours, and the second samples
was drawn two hours after 75g oral glucose loading. The
ﬁrst blood sample was examined for baseline metabolic
proﬁles (fasting blood glucose (FBG), cholesterol, triglyc-
eride, high density lipoprotein cholesterol (HDL-C), low
density lipoprotein cholesterol (LDL-C)), and hormonal
proﬁles (total testosterone, prolactin, thyroid stimulating
hormone(TSH),andcortisol).Thesecondbloodsamplewas
examined for blood glucose and insulin levels.
2.2. Deﬁnitions. Obesity was deﬁned as body mass index
(BMI) ≥25kg/m2 according to the WHO cutoﬀ points
for Asian populations [13]. Central obesity was deﬁned
as WC ≥80cm according to the International Diabetes
Federation (IDF) 2005 [14].
Acanthosis nigricans was a cutaneous condition charac-
terized by a velvety darkening of the skin in the posterior
region of neck, axillae, antecubital fossa, groin, and other
areas [15].
Hypertension was deﬁned as systolic blood pressure
of ≥140mmHg or diastolic blood pressure of ≥90mmHg ,
according to the World Health Organization/International
Society of Hypertension Writing Group (WHO/ISH) 2003
[16].
Dyslipidemia was deﬁned as cholesterol ≥200mg/dL,
LDL-C ≥160mg/dL, HDL-C <50mg/dL, or triglyceride
≥150mg/dL, according to National Cholesterol Education
Program Adult Treatment Panel (NCEP ATP) III [17].
Clinical hyperandrogenism was considered if the partic-
ipants had at least one of the followings: hirsutism (a modi-
ﬁed Ferriman-Gallwey score ≥8), acne, androgenic alopecia,
or virilization. Hyperandrogenemia was deﬁned as total
testosterone >0.8ng/dL, free testosterone >0.006ng/dL, or
dehydroepiandrosterone sulphate (DHEAS) >350mcg/dL
[18].
Abnormal plasma OGTT was classiﬁed according to the
American Diabetes Association (ADA) 2003 criteria [19]a s
follows: (i) impaired fasting glucose (IFG), that is, fasting
blood glucose (FBG) ≥100 and <126mg/dL, (ii) impaired
glucose tolerance test (IGT), that is, 2-hr glucose ≥140 and
<200mg/dL, and (iii) type 2 DM, that is, FBG ≥126mg/dL
or 2-hr glucose ≥200mg/dL. In the present study, IR was
deﬁned as the presence of IFG, IGT, or type 2 DM.
2.3. Laboratory Assays. All laboratory assays were performed
at the laboratory unit of the Department of Clinical Pathol-
ogy,FacultyofMedicineSirirajHospital,MahidolUniversity,
the central laboratory certiﬁed by IS0 15189. All assays were
done using automatic analyzers, Modular P800, Roche (for
total cholesterol, HDL-C, LDL-C, triglycerides, glucose, and
albumin) and Modular E170, Roche (for insulin, TSH, pro-
lactin, cortisol, total testosterone, and DHEAS). Serum-free
testosteronewascalculatedfromserumtotaltestosterone,sex
hormone-binding globulin (SHBG) and albumin using the
online computer program of International Society for the
Study of the Aging Male (ISSAM) [20]. All techniques had
intra- and interassay coeﬃcients of variation (CV) less than
5%.
2.4. Statistical Analysis. Sample size was calculated using a
formula for descriptive data. When an estimated prevalence
of IR = 20% (from our pilot study), precision error of
estimation (25% of P) = 0.05, and α = 0.05, a sample size
of at least 246 was needed.
Statistical analysis was performed using SPSS for Win-
dows, version 11.5. (SPSS Inc.). The normality of dis-
tribution of all continuous variables was checked using
Kolmogorov-Smirnov test. Data were presented in mean
and standard deviation (SD), number (n)a n dp e r c e n t( % ) ,
or odds ratio (OR) and 95% conﬁdence interval (CI), as
appropriate. Univariate analysis using Student t-test, Mann-
Whitney U test (for continuous data), or Chi-square test
or Fisher’s exact test (for categorical data) was applied to
survey potential predictors of IR. Multiple logistic regression
was used to identify the signiﬁcant predictors. All tests were
two-sided, and statistical signiﬁcance was considered to exist
when a P value was <0.05.
3. Results
Table 1 demonstrates clinical and laboratory characteristics
of 250 reproductive-aged Thai women with PCOS. The
mean ± SD of age, body mass index (BMI), and waist
circumference (WC) were 25.4 ± 5.8 years, 26.2 ± 7.6kg/m2,
and 82.3 ± 16.3cm, respectively. Almost all of the partici-
pants (98.4%) presented with oligomenorrhea. Of all par-
ticipants, 97.2% had ultrasonographic polycystic ovary and
49.2% had hyperandrogenism and/or hyperandrogenemia.
Table 2 shows the prevalence of IR in 250 PCOS Thai
women. The overall prevalence was 20.0% which included
3.2% of IFG, 13.6% of IGT, and 5.6% of type 2 DM (3.6%
of FBS ≥126mg/dL, 5.2% of 2-hr glucose ≥200mg/dL, and
3.2% of combined abnormalities).
Table 3 showsclinical predictors forIRin 250PCOS Thai
women. Comparing with the patients without IR, the ones
with IR were older, and had a higher BMI, larger WC, and
higher prevalence of hypertension, acanthosis nigricans, and
dyslipidemia.
Table 4 shows the independent predictors for IR in
250 PCOS Thai women. The results from multiple logisticInternational Journal of Endocrinology 3
Table 1: Characteristics of 250 Thai women with polycystic ovary syndrome.
Characteristics Mean ± SD or n (%, 95% CI)
Age (yr) 25.4 ± 5.8
Body mass index (kg/m2) 26.2 ± 7.6
Waist circumference (cm) 82.3 ± 16.3
Systolic blood pressure (mmHg) 112.5 ± 12.5
Diastolic blood pressure (mmHg) 70.3 ± 9.1
Presence of acanthosis nigricans 68 (27.2, 21.7–32.7)
Clinical criteria
Oligomenorrhea and/or amenorrhea 246 (98.4, 96.8–100)
Hyperandrogenism and/or hyperandrogenemia 123 (49.2, 43.0–55.4)
Ultrasonographic polycystic ovaries 242 (97.2, 95.1–99.2)
Carbohydrate metabolism
Fasting plasma glucose (mg/dL) 85.4 ± 22.9
Fasting plasma insulin (mu/mL) 15.6 ± 34.2
2-hour plasma glucose (mg/dL) 116.4 ± 53.8
2-hour plasma insulin (mu/mL) 106.6 ± 89.0
Lipid proﬁles
Cholesterol (mg/dL) 189.2 ± 37.6
Triglyceride (mg/dL) 103.2 ± 66.2
High-density lipoprotein cholesterol (mg/dL) 55.4 ± 14.6
Low-density lipoprotein cholesterol (mg/dL) 112.0 ± 32.5
Androgen proﬁles
Total testosterone (ng/mL) 0.734 ± 0.387
Free testosterone (ng/mL) 0.014 ± 0.009
Dehydroepiandrosterone sulphate (microgram/dL) 256.8 ± 107.2
Table 2: Prevalence of insulin resistance in 250 Thai women with polycystic ovary syndrome.
Insulin resistance† Prevalence
n % (95% CI)
Overall 50 20.0 (15.04–24.96)
Impaired fasting glucose (IFG)‡ 8 3.2 (1.02–5.38)
Impaired glucose tolerance (IGT) 34 13.6 (9.35–17.85)
Diabetes mellitus (DM) 14 5.6 (2.75–8.45)
Fasting plasma glucose ≥ 126mg/dL 9 3.6 (1.29–5.91)
2h rg l u c o s e≥ 200mg/dL 13 5.2 (2.45–7.95)
Combined abnormalities 8 3.2 (1.02–5.38)
†Insulin resistance: impaired fasting glucose (fasting plasma glucose ≥100 and <126mg/dL), impaired glucose tolerance test (2-hr glucose ≥140 and
<200mg/dL), or the presence of diabetes mellitus.
‡4 women had combined IFG and IGT and 2 women had combined IFG and 2 hr glucose ≥200mg/dL.
CI: conﬁdence interval.
regression analysis by forward stepwise technique showed
that the independent predictors for IR included age of ≥30
years old, WC of ≥80cm, presence of AN, and dyslipidemia,




Insulin resistance is a metabolic disorder caused by the
impairment of insulin function in inducing glucose uptake
and utilization. In clinical setting, various techniques are
used for the diagnosis of IR [21]. These techniques,
including FPG, OGTT, glucose/insulin ratio, homeostasis
model assessment for insulin resistance (HOMA-IR), and
quantitative insulin sensitivity check index (QUICKI), are
shown to correlate well with the gold standard, that is,
euglycemic-hyperinsulinemic clamp [22, 23]. To date, it is
still inconclusive to judge the superiority of one technique
over the others [24, 25]. In the present study, we used FPG
and OGTT as suggested by the Rotterdam ESHRE/ASRM-
sponsored PCOS Consensus Workshop Group [10]. The
overall prevalence of IR in our population was 20.0%.
Interestingly 88.2% (30/34) of the patients with IGT and4 International Journal of Endocrinology
Table 3: Predictors for insulin resistance in 250 Thai women with polycystic ovary syndrome.
Variables N Presence of insulin resistance
n (%) OR (95% CI)
Age, yrs
<30 193 30 (15.5) 1
≥30 57 20 (35.1) 2.94 (1.50–5.73)
Body mass index, kg/m2
<25 135 10 (7.4) 1
≥25 115 40 (34.8) 6.67 (3.15–14.11)
Waist circumference, cm
<80 128 7 (5.5) 1
≥80 122 43 (35.2) 9.41 (4.03–21.96)
Acanthosis nigricans
Absence 182 20 (11.0) 1
Presence 68 30 (44.1) 6.40 (3.28–12.46)
Hypertension†
Absence 234 42 (17.9) 1
Presence 16 8 (50) 4.57 (1.62–12.87)
Dyslipidemia‡
Absence 92 6 (6.5) 1
Presence 158 44 (27.8) 5.53 (2.25–13.58)
Hyperandrogenemia§
Absence 45 4 (8.9) 1
Presence 205 46 (22.4) 2.97 (1.00–8.71)
†Hypertension: systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg.
‡Dyslipidemia: cholesterol ≥200mg/dL, high-density lipoprotein cholesterol <50mg/dL, low-density lipoprotein cholesterol ≥160mg/dL, or triglyceride
≥150mg/dL.
§Hyperandrogenemia: total testosterone >0.8ng/dL, free testosterone >0.006ng/mL, or dehydroepiandrosterone sulphate >350 microgram/dL.
CI: conﬁdence interval; OR: odds ratio.
Table 4: Independence predictors for insulin resistance in 250 Thai
women with polycystic ovary syndrome.
Variables OR (95% CI)∗
Age ≥ 30yrs 2.14 (1.01–4.52)
Waist circumference ≥ 80cm 3.53 (1.28–9.75)
Presence of acanthosis nigricans 2.63 (1.17–5.88)
Dyslipidemia 3.07 (1.16–8.11)
∗Datawereanalyzedusingmultiplelogisticregressionanalysiswithforward
stepwise technique. All factors in Table 3 were included in the analysis.
CI: conﬁdence interval; OR: odds ratio.
85.7% (12/14) of those with type 2 DM did not have IFG.
Our ﬁnding was in line with the previous information that
FPG alone is not a sensitive indicator for IR in women with
PCOS [6, 7, 26].
TheprevalenceofIRinourPCOSwomenwaslowerthan
that of many reports [6, 7, 27] which revealed the prevalence
upto75%.ThediﬀerenceintechniquesusedtodeﬁneIRwas
responsible for such large discrepancy. However, even using
similar deﬁnition, the prevalence of IR in our study was still
lower than that in other studies [6, 28, 29]. This was owing
to the fact of that our study population was relatively young
and thin. Previous studies showed that the prevalence of IR
increased with age and BMI [6, 7].
In the present relatively young and thin PCOS women,
many factors associating with IR were similar to those with
metabolic syndrome [17, 30] as these two conditions are
closely related [31, 32]. These factors included age, central
obesity, presence of acanthosis nigricans, and dyslipidemia.
Hypertension and high BMI were shown to be associated
with IR in univariate analysis but regression analysis indi-
cated that these two variables were not independent factors.
Moreover, the association between IR and central obesity
but not BMI suggested the eﬀect of body fat distribution on
insulinmetabolism.Previousstudiesshowedthatandroidfat
distribution and upper-half type body fat distribution were
linked to insulin resistance in PCOS [33–35].
Hyperandrogenemia, a diagnostic criterion for PCOS,
was shown to be signiﬁcantly associated with IR in our
univariate analysis. Unexpectedly, the association was not
signiﬁcance in the regression analysis. The discrepancy result
between these two analyses indicated that hyperandrogene-
mia had less impact on IR than other factors did. Previous
study demonstrated positive correlations between insulin
and androgen levels [36]. Such correlation existed in both
obese and nonobese PCOS women [37]. The association
between hyperandrogenemia and IR was also demonstrated
in previous reports [38, 39]. The pathophysiology of PCOS
comprising a model of complex interaction between hyper-
androgenemia and IR is well accepted [40]. However, theInternational Journal of Endocrinology 5
results of some studies suggested that these two conditions
might be two separate entities [38, 41]. The absence of
signiﬁcant association between hyperandrogenemia and IR
in the present study might conﬁrm the concept of two
separateentities.However,wecouldnotdisregardtheimpor-
tant of ethnicity on this issue. To date the reference values
of androgens in Asian population are not available. The
reference values used in the present study derived from the
US population, the values of which might not be applicable
for our population.
The results of the present study had to be interpreted
with caution. Due to the limitation of a cross-sectional
study, the prevalence of IR found at the initial visit would
change with time. Therefore, a long-term prospective study
is needed to reveal the actual prevalence in our population,
and the eﬀect of metabolic derangement on future health
status. Furthermore, the majority of our participants were
urbanized women; therefore, they might not represent the
whole picture of PCOS Thai women.
5. Conclusion
The overall prevalence of abnormal OGTT in reproductive-
aged Thai women with PCOS is 20.0%. Clinical predictors
are age of ≥30 years, central obesity, presence of acanthosis
nigricans, and dyslipidemia, but not hyperandrogenemia. It
is probably beneﬁcial to screen for IR in these speciﬁc groups
of PCOS women in order to provide optimum management
for each patient.
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